Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

被引:499
|
作者
Ogitani, Yusuke [1 ]
Hagihara, Katsunobu [2 ]
Oitate, Masataka [2 ]
Naito, Hiroyuki [3 ]
Agatsuma, Toshinori [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Tokyo, Japan
[2] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan
[3] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan
关键词
Antibody-drug conjugate; bystander killing; HER2; T-DM; topoisomerase I inhibitor; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; CATHEPSIN-B; EXPRESSION; LYMPHOMA; THERAPY; PHASE-3; SAFETY;
D O I
10.1111/cas.12966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepared using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan derivative (DX-8951 derivative, DXd). It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression. In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1. We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability. Under a coculture condition of HER2-positive KPL-4 cells and negative MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not. In vivo evaluation was carried out using mice inoculated with a mixture of HER2-positive NCI-N87 cells and HER2-negative MDA-MB-468-Luc cells by using an in vivo imaging system. In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not. Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is observed only in cells neighboring HER2-positive cells, indicating low concern in terms of systemic toxicity. These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.
引用
收藏
页码:1039 / 1046
页数:8
相关论文
共 50 条
  • [41] Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
    Huober, Jens
    Barrios, Carlos H.
    Niikura, Naoki
    Jarzab, Michal
    Chang, Yuan-Ching
    Huggins-Puhalla, Shannon L.
    Pedrini, Jose
    Zhukova, Lyudmila
    Graupner, Vilma
    Eiger, Daniel
    Henschel, Volkmar
    Gochitashvili, Nino
    Lambertini, Chiara
    Restuccia, Eleonora
    Zhang, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2946 - +
  • [42] Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Shimoyama, Tatsu
    Lee, Keun-Wook
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (04) : 816 - +
  • [43] Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
    Gebhart, Geraldine
    Flamen, Patrick
    De Vries, Elisabeth G. E.
    Jhaveri, Komal
    Wimana, Zena
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 : 81S - 88S
  • [44] Evaluation of human epidermal growth factor receptor 2 in breast cancer with a novel specific aptamer
    Chu, ming
    Kang, Jia-rui
    Wang, Wei
    Li, Haichao
    Feng, Jia-hui
    Chu, Zheng-yun
    Zhang, Ming-bo
    Xu, Lan
    Wang, Yue-dan
    CELLULAR & MOLECULAR IMMUNOLOGY, 2017, 14 (04) : 398 - 400
  • [45] Surface plasmon resonance investigations of human epidermal growth factor receptor 2
    Martin, V. S.
    Sullivan, B. A.
    Walker, K.
    Hawk, H.
    Sullivan, B. P.
    Noe, L. J.
    APPLIED SPECTROSCOPY, 2006, 60 (09) : 994 - 1003
  • [46] Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples
    Oono, Yasuhiro
    Kuwata, Takeshi
    Takashima, Kenji
    Shinmura, Kensuke
    Hori, Keisuke
    Yoda, Yusuke
    Ikematsu, Hiroaki
    Shitara, Kohei
    Kinoshita, Takahiro
    Yano, Tomonori
    GASTRIC CANCER, 2019, 22 (02) : 335 - 343
  • [47] Dynamical Rearrangement of Human Epidermal Growth Factor Receptor 2 upon Antibody Binding: Effects on the Dimerization
    Magalhaes, Pedro R.
    Machuqueiro, Miguel
    Almeida, Jose G.
    Melo, Andre
    Cordeiro, M. Natalia D. S.
    Verde, Sandra Cabo
    Gumus, Zeynep H.
    Moreira, Irina S.
    Correia, Joao D. G.
    Melo, Rita
    BIOMOLECULES, 2019, 9 (11)
  • [48] Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance
    Sami, Manal M.
    Sherief, Mahmoud H.
    El-Abaseri, Taghrid B.
    El-Sakka, Ahmed, I
    El-Serafi, Ahmed T.
    UROLOGIA JOURNAL, 2023, 90 (02) : 248 - 260
  • [49] First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
    Kim, Sung-Bae
    Meric-Bernstam, Funda
    Kalyan, Aparna
    Babich, Aleksei
    Liu, Rong
    Tanigawa, Takahiko
    Sommer, Anette
    Osada, Motonobu
    Reetz, Frank
    Laurent, Dirk
    Wittemer-Rump, Sabine
    Berlin, Jordan
    TARGETED ONCOLOGY, 2019, 14 (05) : 591 - 601
  • [50] Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer
    Van den Mooter, Tom
    Teuwen, Laure-Anne
    Rutten, Annemie
    Dirix, Luc
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (05) : 749 - 760